Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib

Anlotinib is a receptor tyrosine kinase inhibitor with potential anti-neoplastic and anti-angiogenic activities. It has been approved for the treatment of non-small-cell lung cancer. Lysosomes are acidic organelles and have been implicated in various mechanisms of cancer therapeutics. However, the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xin, Shu, Yuhan, Yan, Peiyi, Huang, Hongliang, Gao, Ruilan, Xu, Mengting, Lu, Liqin, Tian, Jingkui, Huang, Dongsheng, Zhang, Jianbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445181/
https://www.ncbi.nlm.nih.gov/pubmed/32839434
http://dx.doi.org/10.1038/s41419-020-02904-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445181/
https://www.ncbi.nlm.nih.gov/pubmed/32839434
http://dx.doi.org/10.1038/s41419-020-02904-0

Ejemplares similares